Antitubercular nanocarrier monotherapy: Study of In Vivo efficacy and pharmacokinetics for rifampicin
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
S10 OD023524
NIH HHS - United States
PubMed
32067995
DOI
10.1016/j.jconrel.2020.02.026
PII: S0168-3659(20)30116-4
Knihovny.cz E-resources
- Keywords
- BALB/c mice, Drug delivery system, Histopathology, Nanoparticles, Pharmacokinetics, Rifampicin, Tuberculosis,
- MeSH
- Antitubercular Agents MeSH
- Antibiotics, Antitubercular * pharmacokinetics MeSH
- Mycobacterium tuberculosis * MeSH
- Mice, Inbred BALB C MeSH
- Mice MeSH
- Nanostructures MeSH
- Drug Carriers MeSH
- Rifampin * pharmacokinetics MeSH
- Tuberculosis * drug therapy MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antitubercular Agents MeSH
- Antibiotics, Antitubercular * MeSH
- Drug Carriers MeSH
- Rifampin * MeSH
Tuberculosis represents a major global health problem for which improved approaches are needed to shorten the course of treatment and to combat the emergence of resistant strains. The development of effective and safe nanobead-based interventions can be particularly relevant for increasing the concentrations of antitubercular agents within the infected site and reducing the concentrations in the general circulation, thereby avoiding off-target toxic effects. In this work, rifampicin, a first-line antitubercular agent, was encapsulated into biocompatible and biodegradable polyester-based nanoparticles. In a well-established BALB/c mouse model of pulmonary tuberculosis, the nanoparticles provided improved pharmacokinetics and pharmacodynamics. The nanoparticles were well tolerated and much more efficient than an equivalent amount of free rifampicin.
References provided by Crossref.org
